Single-chain variable fragment: Difference between revisions

Revision as of 06:41, 19 July 2015

Latest revision as of 06:40, 25 May 2025

(35 intermediate revisions by 24 users not shown)

Line 1:

{{short description|Fragment}}

[[File:ScFv-rotation.gif|300px|thumb|Rotating scFv fragment with highlighted complementarycomplementarity determining regions (CDRs)]]

[[File:Single chain variable fragment.svg|thumb|The two possible structures of a single-chain variable fragment, with the antigen binding sites including the [[N-terminus|N-termini]] on the left and the [[C-terminus|C-termini]] on the right. The linker peptides are shown as arrows.]]

A '''single-chain variable fragment''' ('''scFv''') is not actually a [[Antibody fragment|fragment]] of an antibody, but instead is a [[fusion protein]] of the variable regions of the [[Immunoglobulin heavy chain|heavy]] (V_H) and [[Immunoglobulin light chain|light chains]] (V_L) of [[immunoglobulins]], connected with a short linker [[peptide]] of ten to about 25 [[amino acid]]s.<ref>{{cite journal | last1 = Huston, | first1 = J. S., | last2 = Levinson, | first2 = D., | last3 = Mudgett-Hunter, | first3 = M., | last4 = Tai, | first4 = M. S., | last5 = Novotný, | first5 = J., | last6 = Margolies, | first6 = M. N., …| last7 = Crea, | first7 = R. (| year = 1988). | title = Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. | journal = Proceedings of the National Academy of Sciences of the United States of America, | volume = 85( | issue = 16),| pages = 5879–5883 | doi=10.1073/pnas.85.16.5879| pmid = 3045807 | pmc = 281868 | bibcode = 1988PNAS...85.5879H | doi-access = free }}</ref> The linker is usually rich in [[glycine]] for flexibility, as well as [[serine]] or [[threonine]] for solubility, and can either connect the [[N-terminus]] of the V_H with the [[C-terminus]] of the V_L, or ''vice versa''.<ref name="Schirrmann">{{cite webjournal|url=http://edoc.hu-berlin.de/dissertationen/schirrmann-thomas-2005-03-18/HTML/|language=Germande|last=Schirrmann|first=Thomas|title=Tumorspezifisches Targeting der humanen Natürlichen Killerzellinie YT durch Gentransfer chimärer Immunglobulin-T-Zellrezeptoren|date=8 November 2004|___location=Berlin|doi=10.18452/15246}}</ref>

This protein retains the specificity of the original immunoglobulin, despite removal of the constant regions and the introduction of the linker.<ref name="Peterson" /> The image to the right shows how this modification usually leaves the specificity unaltered.

These molecules were created to facilitate [[phage display]], where it is highly convenient to express the [[Fragment antigen-binding|antigen-binding ___domain]] as a single peptide. As an alternative, scFv can be created directly from [[subcloning|subcloned]] heavy and light chains derived from a [[hybridoma]]. ScFvs have many uses, e.g., [[flow cytometry]], [[immunohistochemistry]], and as antigen-binding domains of [[artificial T cell receptors]] (chimeric antigen receptor).

Unlike [[monoclonal antibodies]], which are often produced in mammalian cell cultures, scFvs are more often produced in bacteria cell cultures such as ''[[E. coli]]''.<ref name="Peterson">{{cite journal|title=Monoclonal Antibody Form and Function: Manufacturing the Right Antibodies for Treating Drug Abuse|lastlast1=Peterson|firstfirst1=Eric|journal=AAPS Journal|year=2006|volume=8|issue=2|pages=E383–E390|url=http://www.aapsj.org/view.asp?art=aapsj080243|doi=10.1208/aapsj080243|pmid=16796389|last2=Owens|first2=SM|last3=Henry|first3=RL|pmc=3231570}}</ref>

==Purification==

Single-chain variable fragments lack the constant [[Fc region]] found in complete antibody molecules, and, thus, the common binding sites (e.g., [[Proteinprotein G]]) cannot be used to purify antibodies. These fragments can often be purified or immobilized using [[Proteinprotein L]], since Proteinprotein L interacts with the variable region of kappa light chains. More commonly, scientists incorporate a six histidine tag on the c-terminus of the scFv molecule and purify them using immobilized metal affinity chromatography (IMAC). For unknown reasons, someSome scFv can also be captured by [[Proteinprotein A]] if they contain a human VH3 ___domain.<ref name="Vostakolaei 14711–14724">{{Cite journal |last1=Vostakolaei |first1=Mehdi Asghari |last2=Molavi |first2=Ommoleila |last3=Hejazi |first3=Mohammad Saeid |last4=Kordi |first4=Shirafkan |last5=Rahmati |first5=Saman |last6=Barzegari |first6=Abolfazl |last7=Abdolalizadeh |first7=Jalal |date=September 2019 |title=Isolation and characterization of a novel scFv antibody fragments specific for Hsp70 as a tumor biomarker |url=https://onlinelibrary.wiley.com/doi/10.1002/jcb.28732 |journal=Journal of Cellular Biochemistry |language=en |volume=120 |issue=9 |pages=14711–14724 |doi=10.1002/jcb.28732 |pmid=30998271 |s2cid=121351794 |issn=0730-2312|url-access=subscription }}</ref><ref>{{Cite journal|url=https://pubmed.ncbi.nlm.nih.gov/9186782-staphylococcal-protein-a-binding-to-vh3-encoded-immunoglobulins/|pmid = 9186782|year = 1997|last1 = Potter|first1 = K. N.|last2 = Li|first2 = Y.|last3 = Pascual|first3 = V.|last4 = Capra|first4 = J. D.|title = Staphylococcal protein a binding to VH3 encoded immunoglobulins|journal = International Reviews of Immunology|volume = 14|issue = 4|pages = 291–308|doi = 10.3109/08830189709116521}}</ref><ref>{{Cite journal |last1=Kordi |first1=Shirafkan |last2=Rahmati-Yamchi |first2=Mohammad |last3=Asghari Vostakolaei |first3=Mehdi |last4=Barzegari |first4=Abolfazl |last5=Abdolalizadeh |first5=Jalal |date=2019-02-21 |title=Purification of a Novel Anti-VEGFR2 Single Chain Antibody Fragmentand Evaluation of Binding Affinity by Surface Plasmon Resonance |url=https://apb.tbzmed.ac.ir/Abstract/apb-22975 |journal=Advanced Pharmaceutical Bulletin |language=en |volume=9 |issue=1 |pages=64–69 |doi=10.15171/apb.2019.008 |issn=2228-5881 |pmc=6468230 |pmid=31011559}}</ref>

==Bivalent and trivalent scFvs==

[[File:Polyvalent single-chain variable fragments.svg|thumb|300px|Structure of divalent (top) and trivalent (bottom) scFvs, tandem (left) and di-/trimerisation format (right)]]

''Divalent'' (or ''bivalent'') single-chain variable fragments (di-scFvs, bi-scFvs) can be engineered by linking two scFvs. This can be done by producing a single peptide chain with two V_H and two V_L regions, yielding ''tandem scFvs''.<ref>{{cite journal|title=Development of tumor targeting anti-MUC-1 multimer: effects of di-scFv unpaired cysteine ___location on PEGylation and tumor binding|first5=SJ|last5=Denardo|first4=GL|last4=Denardo|first3=XB|last3=Shi|first2=A|last2=Natarajan |lastlast1=Xiong|firstfirst1=Cheng-Yi|journal=Protein Engineering Design and Selection|year=2006|volume=19|issue=8|pmid=16760193|pages=359–367|url=http://peds.oxfordjournals.org/cgi/content/full/19/8/359|doi=10.1093/protein/gzl020|doi-access=free}}</ref><ref>{{cite journal|title=A revival of bispecificbispecific antibodies|first1=Peter|last1=Kufer|first2=Ralf|last2=Lutterbüse|first3=Patrick A.|last3=Baeuerle|journal=Trends in Biotechnology|volume=22|issue=5|pages=238–244|year=2004|url=http://www.micromet.de/fileadmin/template/main/pdf/publications_147881aaf61df52304237f0ee7f0cf2a.pdf|doi=10.1016/j.tibtech.2004.03.006|pmid=15109810}}</ref> Another possibility is the creation of scFvs with linker peptides that are too short for the two variable regions to fold together (about five amino acids), forcing scFvs to dimerize. This type is known as ''diabodies''.<ref>{{cite journal|pmid=8341653|title="Diabodies": small bivalent and bispecific antibody fragments|lastlast1=Hollinger|firstfirst1=Philipp|volume=90|issue=14|pmc=46948|date=July 1993|pages=6444–8|last2=Prospero|first2=T|last3=Winter|first3=G|journal=Proceedings of the National Academy of Sciences of the United States of America|doi=10.1073/pnas.90.14.6444|bibcode=1993PNAS...90.6444H|doi-access=free}}</ref> Diabodies have been shown to have [[dissociation constant]]s up to 40-fold lower than corresponding scFvs, meaning that they have a much higher [[affinity (pharmacology)|affinity]] to their target. Consequently, diabody drugs could be dosed much lower than other therapeutic antibodies and are capable of highly specific targeting of tumors in vivo.<ref name="Adams">{{cite journal|pmid=9652755|year=1998|last1=Adams|first1=GP|last2=Schier|first2=R|last3=McCall|first3=AM|last4=Crawford|first4=RS|last5=Wolf|first5=EJ|last6=Weiner|first6=LM|last7=Marks|first7=JD|title=Prolonged in vivo tumour retention of a human diabody targeting the extracellular ___domain of human HER2/neu|volume=77|issue=9|pages=1405–12|pmc=2150193|journal=British journalJournal of cancerCancer|doi=10.1038/bjc.1998.233}}</ref> Still shorter linkers (one or two amino acids) lead to the formation of trimers, so-called ''triabodies'' or ''tribodies''. ''Tetrabodies'' have also been produced. They exhibit an even higher affinity to their targets than diabodies.<ref>{{cite journal|title=Di-, tri- and tetrameric single chain Fv antibody fragments against human CD19: effect of valency on cell binding|first4=M|last4=Little|first3=G|last3=Moldenhauer|journal=FEBS Letters|first2=SM|volume=453|last2=Kipriyanov|issue=1|pages=164–168|firstfirst1=F.|lastlast1=Le Gall|pmid=10403395|doi=10.1016/S0014-5793(99)00713-9|year=1999|s2cid=20213440|doi-access=free}}</ref>

All of these formats can be composed from variable fragments with specificity for two different antigens, in which case they are types of [[bispecific antibodies]].<ref>{{cite journal|pmid=11388794|year=2001|last1=Dincq|first1=S|last2=Bosman|first2=F|last3=Buyse|first3=MA|last4=Degrieck|first4=R|last5=Celis|first5=L|last6=De Boer|first6=M|last7=Van Doorsselaere|first7=V|last8=Sablon|first8=E|title=Expression and purification of monospecific and bispecific recombinant antibody fragments derived from antibodies that block the CD80/CD86-CD28 costimulatory pathway|volume=22|issue=1|pages=11–24|doi=10.1006/prep.2001.1417|journal=Protein expressionExpression and purificationPurification}}</ref><ref>{{cite webthesis|first1=C|last1=Kellner|url=http://www.opus.ub.uni-erlangen.de/opus/volltexte/2009/1235/|title=Entwicklung und Charakterisierung bispezifischer Antikörper-Derivate zur Immuntherapie CD19-positiver Leukämien und Lymphome|trans_titletrans-title=Development and characterisation of bispecific antibody derivatives for the immunotherapy of CD19-positive leukaemia and lymphoma|language=Germande, Englishen|publisher=Friedrich-Alexander-Universität|___location=Erlangen-Nürnberg|year=2008}}</ref> The furthest developed of these are bispecific tandem di-scFvs, known as [[bi-specific T-cell engager]]s (BiTEsBiTE antibody constructs).

==Examples==

* [[Pexelizumab]], a scFv binding to [[Complement component 5|component 5]] of the [[complement system]] and useddesigned to reduce side effects of [[cardiac surgery]]<ref>{{cite journal|pmid=15331798|year=2004|last1=Mathew|first1=JP|last2=Shernan|first2=SK|last3=White|first3=WD|last4=Fitch|first4=JC|last5=Chen|first5=JC|last6=Bell|first6=L|last7=Newman|first7=MF|title=Preliminary report of the effects of complement suppression with pexelizumab on neurocognitive decline after coronary artery bypass graft surgery|volume=35|issue=10|pages=2335–9|doi=10.1161/01.STR.0000141938.00524.83|journal=Stroke;: aA journalJournal of cerebralCerebral circulationCirculation|doi-access=free}}</ref>

* C6.5, a diabody targeting [[HER2/neu]]<ref name="Adams" /> found in some [[breast cancer]]s

* [[Brolucizumab]], a scFV binding to VEGF-A and used to treat wet age-related macular degeneration

* '''G6A''', a scFV binding to human Hsp70.1 and can be used to target this protein as a potential marker in vast cancers.<ref name="Vostakolaei 14711–14724"/>

==References==

Line 27 ⟶ 30:

{{DEFAULTSORT:Single-Chain Variable Fragment}}

[[Category:Monoclonal antibodies|.]]